Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

Little Green Pharma’s proposed acquisition of Cannatrek has moved a step closer to the finish line, with the key regulatory overhang now looking more manageable than feared.

The company says Cannatrek has reached an in-principle agreement with the Therapeutic Goods Administration over alleged historical breaches of the Therapeutic Goods Act and related regulations. The matter relates to Cannatrek’s past advertising of therapeutic goods, a sensitive area for medicinal cannabis companies given the tight controls around promotion, patient access and compliant communications.

Importantly for LGP investors, the expected civil penalty is understood to sit within the economic parameters already built into the transaction. LGP does not yet know the exact quantum of the penalty, and it has stressed that the amount is material. However, the company believes it remains within the limits covered by the contingent value share, or CV Share, mechanism.

That distinction matters. The Cannatrek deal has always carried a regulatory wrinkle, and the CV Shares appear designed to stop unknown liabilities from landing too heavily on existing LGP shareholders. While the penalty is not immaterial, the market is likely to focus on the fact that the issue appears to have been ring-fenced rather than allowed to become a deal-breaker.

The $6.5 million kicker

Just as notable is Cannatrek’s expected capital contribution at completion. LGP says Cannatrek anticipates bringing an additional estimated $6.5 million of capital into the merged group above the minimum agreed under the transaction documents.

For a medicinal cannabis business, cash is not a cosmetic detail. The sector has been littered with companies that discovered too late that cultivation capacity, regulatory compliance, working capital, distribution and overseas expansion all require hard dollars rather than PowerPoint ambition.

An extra $6.5 million would provide the combined entity with a little more breathing room as it seeks to integrate operations and press its advantage in Australia and offshore markets. LGP already has vertically integrated operations across Australia and Europe, including production assets in Denmark and Australia. The company says it supplies medicinal cannabis products into Australia and more than 12 export markets, with positions in France, Germany and the UK.

The Cannatrek acquisition, if completed, would add further scale in a domestic market where brand presence, prescribing channels, product breadth and compliance discipline all matter.

Conditions precedent appear on track

LGP says the parties do not currently anticipate any issues satisfying the remaining conditions precedent to the scheme. That is another useful signal for investors watching the transaction timeline.

Schemes of arrangement are legal and procedural beasts, and even friendly deals can stall if conditions are not met, court approvals are delayed or shareholder support wobbles. The company’s message is that the machinery is still moving.

The next key event is the LGP general meeting, scheduled for 3.30pm Perth time on 22 May 2026. Shareholders will vote on the resolution to approve the issue of new LGP ordinary shares and new LGP CV Shares connected with the Cannatrek scheme consideration.

The board has unanimously recommended shareholders vote in favour of the resolution, provided no superior proposal emerges. Each LGP director also intends to vote any shares they control in favour of the resolution on the same basis.

A virtual vote with a tight timetable

The general meeting will be held virtually via Zoom. Shareholders who want to vote live at the meeting must notify the company secretary by 3.30pm Perth time on 20 May 2026. The voting eligibility record time is 5.00pm Perth time on the same day.

Proxy votes already submitted remain valid. Shareholders who have not voted, or who want to amend their vote, can do so electronically through the share registry before the proxy cut-off.

If shareholders approve the resolution and the remaining steps proceed as expected, the second court hearing is scheduled for 25 May 2026, with the scheme expected to become effective the same day. The implementation date, when consideration securities are due to be issued, is scheduled for 1 June 2026.

Why the update matters

For investors, this is less about medicinal cannabis glamour and more about transaction risk.

The TGA matter was the obvious loose thread. A material civil penalty is never welcome, but LGP’s view that it falls within the pre-agreed CV Share framework reduces the likelihood of a nasty surprise outside the negotiated deal economics. The additional capital expected from Cannatrek also helps the optics, particularly in a sector where balance sheet durability remains a recurring investor concern.

That said, the transaction is not yet complete. The penalty amount has not been disclosed, shareholders still need to vote, and court approval remains part of the process. Integration risk will also matter once the legal formalities are done.

For now, LGP has given investors a clearer read on the big regulatory question hanging over the Cannatrek acquisition. The answer is not entirely pain-free, but it looks containable. In medicinal cannabis, where the difference between growth story and cautionary tale often comes down to compliance and cash, that is no small thing.

Swift TV Ltd has taken its enterprise in-room entertainment platform out of the work camp and aged-care corridor and into the holiday resort, securing its first hospitality agreement with Daydream Island Resort in Queensland’s Whitsundays.

The deal will see Swift TV deployed across the premium resort’s 244 rooms as a recurring subscription platform. Installation is expected to start shortly, with subscription revenue to begin as rooms are commissioned.

For a micro-cap technology play, this is not yet a numbers-driven contract. Swift has not disclosed contract value, subscription pricing, expected annual recurring revenue or installation margins. But strategically, the agreement matters because it gives Swift a glossy reference site in a sector where buying decisions are often influenced by proof, peer adoption and whether the thing actually works when a guest wants to watch Netflix before dinner.

Why investors should care about the sector shift

Swift’s core proposition is an enterprise connected TV platform for managed accommodation. Historically, that has meant sectors such as mining, oil and gas and aged care, where operators need entertainment, communication tools and centralised control across large room networks.

Hospitality is a natural extension, but not an automatic win. Hotels and resorts want guest-facing technology that improves the stay, reduces friction and ideally opens extra revenue channels. They also need operational controls: secure logins, automatic logout, messaging capability and systems that do not require staff to play IT helpdesk every time a guest cannot cast from their phone.

That is where Swift is trying to position itself. The Daydream Island agreement gives the company a visible, premium resort deployment that can be shown to hotel groups and accommodation operators. In enterprise software and hardware, especially at the smaller end of the ASX, a reference site can be worth more than a brochure. It lets management say: come and see it working.

Managing director and chief executive Brian Mangano described the agreement as “an important step” in expanding Swift TV into global hospitality, saying it demonstrated the platform’s ability to deliver “a more advanced, revenue-generating in-room experience”. He added that the site is expected to support broader deployment opportunities across hotel portfolios.

The Netflix timing is handy

The resort win also follows a useful product milestone. Swift recently secured final Netflix approval for integration within its platform after a multi-year certification process involving Google and Netflix. The company said the integration allows enterprise customers to provide direct access to personal streaming subscriptions while retaining controls such as secure access, auto logout and emergency messaging over active viewing.

That matters in hospitality because the humble hotel television has become a surprisingly contested bit of real estate. Guests increasingly expect the same streaming convenience they have at home, while operators want a managed system that protects privacy and avoids operational nuisance. A platform that can combine entertainment, resort communication and enterprise controls has a clearer pitch than a plain screen with a few apps bolted on.

Market reaction and valuation context

Swift TV remains firmly in the speculative micro-cap camp. The ASX company page showed STV at $0.012, up 20%, with market capitalisation of $11.25 million when checked. Market Index describes Swift as a technology company delivering an entertainment and engagement platform, with services including consulting, design and installation.

At that size, individual customer wins can move sentiment quickly, especially when they suggest a broader addressable market. But the market will want more than a postcard from Daydream Island. The key investor questions are how quickly rooms are commissioned, what recurring revenue per room looks like, whether installation costs are recovered attractively and whether the resort reference site converts into multi-property hotel group deals.

The investor read-through

The positive interpretation is that Swift is showing cross-sector scalability. A platform that can serve mining villages, aged care facilities and a Whitsundays resort has a broader commercial story than a niche accommodation-tech product. The recurring subscription structure is also the right model if Swift can keep adding rooms without customer acquisition costs running ahead of revenue.

The more cautious view is that this is still an early-stage hospitality beachhead, not yet proof of material scale. Investors should note the absence of financial terms and the staged nature of revenue recognition as rooms are commissioned. A 244-room resort is useful, but the investment case improves only if it becomes the first domino rather than a one-off showpiece.

For now, Swift has checked into a more glamorous vertical and given itself a credible calling card. The next test is whether management can turn the Daydream Island deployment into a pipeline of hotel portfolio wins - because in micro-cap tech, the minibar money is nice, but the chain-wide rollout is where the real bill gets interesting.

Adisyn has taken a potentially important step in taking its graphene-based stealth materials program out of the laboratory and towards the factory floor, signing a memorandum of understanding with Israeli plastics heavyweight Raval A.C.S. Ltd.

The agreement sits with Adisyn subsidiary 2D Radar Absorbers, which is developing graphene-enhanced injection-moulded components designed to absorb radar signals in drones and unmanned aerial vehicles. For investors, the key point is not merely that Adisyn has found another research partner. It is that the company has teamed up with an industrial manufacturer that already makes precision thermoplastic and structural composite parts for global automotive customers.

That matters because advanced materials stories often get stuck in the dreaded “lab-to-fab” valley. A prototype might work on a benchtop, but scaling it into a repeatable, certifiable and cost-effective product can become a long and expensive detour. Adisyn’s argument is that working with Raval’s serial production equipment from the outset could cut that transition from years to months.

Why Raval matters

Raval is no cottage-industry moulding shop. The company reported calendar 2025 revenue of about €201 million, EBITDA of around €33 million and an order backlog of roughly €1.243 billion. It employs about 1,220 people across 11 facilities in North America, Western and Eastern Europe, China and Israel.

Its customer list includes major automotive names such as Volkswagen, BMW, Mercedes, GM and Porsche, with the quality systems to match. Those credentials include IATF 16949, ISO 14001, ISO 45001, VDA 6.3 and TISAX accreditations.

For Adisyn, the attraction is obvious. Automotive-grade manufacturing is not the same as defence qualification, but it does suggest a discipline around tooling, repeatability, process control and supply-chain compliance. Those qualities are essential if graphene-enhanced radar-absorbing parts are to move beyond science project status.

The commercial structure

Under the MOU, Raval will lead the plastics and moulding development, manufacture sample parts and test mechanical properties. Adisyn’s 2D Radar will lead the graphene and two-dimensional materials work, as well as radar absorption testing with Tel Aviv University.

Each party will fund its own development work, while prototypes ordered by prospective customers will be jointly funded. 2D Radar may also seek non-dilutive funding from MAFAT or the Israeli Innovation Authority, which could help cover a portion of Raval’s development costs if approved.

The deal sets out a 12-month period to demonstrate material technical progress, such as successful radar absorption testing against agreed benchmarks, completion of the workplan or a customer prototype request. The parties then have an 18-month window to determine whether the collaboration is commercially viable.

If the milestones stack up, Adisyn and Raval intend to negotiate a 50:50 joint venture to manufacture and supply graphene-based products for drones and UAVs. The proposed JV may receive manufacturing exclusivity in Israel only, with 2D Radar licensing its radar absorption technology to the vehicle in return for a royalty on gross revenues.

That final point is worth noting. The exclusivity is not global, which preserves optionality for Adisyn outside Israel. It also means the royalty model could give 2D Radar a revenue stream tied to sales rather than solely relying on manufacturing margins.

Management’s pitch

Adisyn managing director Arye Kohavi called the agreement “a major step forward” for the company’s stealth materials program, pointing to Raval’s engineering depth, quality systems and manufacturing footprint.

“For the Israeli Ministry of Defense and global drone manufacturers, our ability to move from development to production in months - rather than years - is a critical differentiator,” Kohavi said.

He added that the arrangement, combined with Adisyn’s exclusive worldwide rights to graphene-based radar absorption technology from Tel Aviv University, gave the company an integrated stealth materials platform “from underlying science through to industrial-scale production”.

Investor read-through

The opportunity is enticing, but this is still an MOU, not a purchase order. There is no disclosed customer contract, no revenue guidance and no confirmed JV yet. Technical validation remains the first hurdle, followed by commercial validation, definitive agreements and customer adoption.

Still, the strategic logic is sound. Defence drone demand is being reshaped by modern battlefield realities, where radar signature, survivability and speed of deployment are no longer niche concerns. If Adisyn can prove that graphene-enhanced injection-moulded components deliver useful radar absorption while being manufacturable at scale, the company may have something more substantial than a clever materials platform.

For now, investors should see the Raval agreement as a de-risking step rather than a commercial endgame. It does not prove the technology will sell, but it does address one of the most common fail points for advanced materials hopefuls: finding a credible path from promising science to repeatable industrial production.

Amplia Therapeutics has given investors a fresh reason to look beyond pancreatic cancer, signing an agreement with the Australia New Zealand Gynaecological Oncology Group to run a new ovarian cancer study of its lead drug narmafotinib.

The planned PRROSE trial will test narmafotinib alongside standard chemotherapy, carboplatin and paclitaxel, in about 15-20 patients with high-grade serous ovarian cancer who have responded poorly to initial platinum-based chemotherapy ahead of planned interval debulking surgery. That is a small study, but for an ASX biotech with a market value around $72 million, it is potentially useful clinical optionality without requiring a swing-for-the-fences phase three cheque just yet.

Why ovarian cancer, and why now?

The logic is biological as much as commercial. Amplia says ovarian cancer is a major target for FAK inhibition because these tumours often show higher FAK expression and a fibrous tumour environment. FAK, or focal adhesion kinase, is involved in the way cancer cells interact with their surroundings, and narmafotinib is designed to inhibit this pathway.

The unmet need is also clear. Amplia says about one in five ovarian cancer patients do not respond adequately to initial chemotherapy, which can limit their ability to proceed to surgery and worsen outcomes. PRROSE will look first at safety, but it will also explore whether adding narmafotinib can increase the proportion of patients who become eligible for successful surgical resection. That gives the trial a practical clinical question: can the drug help turn a poor pre-surgery responder into a better surgical candidate?

The credibility kicker: ANZGOG

For investors, the ANZGOG tie-up matters. This is not Amplia simply adding another line to a slide deck. ANZGOG is the peak gynaecological cancer research organisation across Australia and New Zealand, with a broad clinical trials network spanning major hospitals. The study is investigator initiated, led by Dr Gwo Yaw Ho of Monash Health and Monash University, and sponsored and coordinated by ANZGOG.

Chief executive Dr Chris Burns framed the study as a deliberate broadening of the FAK inhibitor program. “Patients with ovarian cancer who do not respond to initial chemotherapy have very limited treatment options and this study will provide an opportunity to assess whether narmafotinib can improve outcomes for these patients,” he said.

Dr Ho added that the trial reflects ANZGOG’s ability to bring together clinical investigators in areas of high unmet need, with the study designed to generate meaningful evidence for future treatment options.

Pancreatic data remains the main valuation anchor

The ovarian study is useful, but the market will still be taking most of its cues from pancreatic cancer. Amplia’s ACCENT trial has been testing narmafotinib with gemcitabine and Abraxane in first-line advanced pancreatic cancer. The company’s latest ovarian cancer release cites a 31% response rate and interim progression-free survival of 7.6 months for ACCENT, while subsequent market reports on the March mature ACCENT data referred to a centrally reviewed objective response rate of 35.9% and median overall survival of 11.1 months.

That broader context is important because narmafotinib’s investment case is no longer just “interesting science”. It now has human efficacy signals, albeit from studies that still need the harder proof demanded by larger, controlled trials.

The wrinkle: AMPLICITY reminded everyone biotech is not knitting

Investors should also keep the April AMPLICITY halt in mind. Amplia stopped recruitment in that pancreatic cancer trial after three dose-limiting toxicities linked to the FOLFIRINOX chemotherapy regimen, while stating no toxicity concerns had been identified with narmafotinib. The episode does not torpedo the drug, but it does underline the everyday reality of oncology drug development: combinations can be as tricky as the compound itself.

That makes PRROSE interesting because it pairs narmafotinib with a different standard chemotherapy backbone in a different fibrotic cancer setting. Success would not just add an ovarian cancer opportunity; it would also support the broader contention that FAK inhibition can travel across tumour types.

The investor read-through

PRROSE is early, small and exploratory. It will not deliver registration-grade evidence, and investors should not dress it up as such. But it does three useful things for Amplia.

It broadens narmafotinib beyond pancreatic cancer, brings a respected oncology trials group into the tent, and collects tissue and blood biomarker data that could sharpen future patient selection. In biotech land, where the distance between “promising” and “proven” can be measured in years and millions of dollars, that is a sensible next move.

The share price will still dance to pancreatic data, trial design, funding runway and regulatory progress. But with ovarian cancer now formally in the clinic queue, Amplia has added another string to the narmafotinib bow - and this one has a clear biological rationale rather than a mere whiff of opportunism.

X2M Connect has sketched out a much larger Australian growth plan, signing a non-binding memorandum of understanding with Mawson Business Advisory to develop what it calls an Integrated Smart Community Offering, or ISCO. The pitch is bold: give retirement villages, land lease communities, caravan parks, residential subdivisions and master planned estates one technology and operations stack rather than a patchwork of up to 20 vendors.

For investors, the attraction is not merely the gadgetry. X2M wants to be the prime contractor on each estate agreement, taking all revenue and retaining the right to add margin on subcontracted services. Contracts are intended to run for 10 years, which would push the company further towards the kind of long-duration recurring revenue model small-cap tech investors tend to prize.

The retirement village angle

The target market is not trivial. X2M cites more than 2,500 retirement villages in Australia, housing around 200,000 residents, with the retirement village sector carrying a capital value of $6.2 billion in 2026. The land lease community sector adds more than 900 communities and about 70,000 Australians.

The ISCO bundle would include automated meter reading for electricity, water and gas, AI-driven utility management, resident billing, land lease administration, VoIP and mobile virtual network operator services, community solar and batteries, maintenance and help desk support. In plainer terms, X2M is trying to move from selling smart infrastructure into becoming an embedded operating platform for private communities.

That is potentially more lucrative, but also more complex. Selling meter infrastructure is one thing. Running a single-bill, connectivity, utility and estate management ecosystem is another. Investors should note the MoU is non-binding, so the next proof point is conversion into executable estate contracts.

Private 5G is the sizzle, but data is the steak

The eye-catching claim is that private 5G infrastructure could replace NBN connections inside estates. X2M says the network could support real-time machine-to-machine communication for applications such as smart street lighting, automated valve control, driverless shuttles, energy balancing and predictive fault detection.

Still, the deeper commercial logic sits in X2M’s data platform. The company’s Flexible Micro Engine is designed to connect with different meters, sensors, devices, networks and protocols. That device-agnostic capability matters because estates are unlikely to have neat, uniform infrastructure. X2M says its platform turns raw utility and device signals into structured, AI-ready data, which is the foundation for operating these communities more efficiently.

The Mawson relationship is also important. Mawson brings property, landowner and facilities management relationships, and is described as one of X2M’s largest shareholders. Mawson Advisory managing director Julian Kirzner said the single-title multiple-dwelling market represents a “significant opportunity for integrated facilities management services” and described X2M’s platform as “world leading” based on its international deployments.

The revenue prize and the assumptions

X2M says the partnership can add momentum to its Australian pipeline, which already stands at about 5,800 lots across binding and non-binding agreements, with an estimated value of $11.8 million if all households adopt the company’s offering. That last phrase is doing some heavy lifting. Full household adoption is an upside case, not banked revenue.

The company also says the total addressable market of its existing utility customers exceeds $600 million in upfront revenue and $40 million in annual recurring revenue, again assuming all households across those municipalities adopt X2M’s technology.

X2M’s installed base gives the story some ballast. The company says it has connected more than 500,000 devices and serves 89 enterprise and government customers across South Korea, Japan, Taiwan, the Middle East and Australia. It also says about half of its existing customers place repeat orders, suggesting the business can deepen relationships once it wins a seat at the table.

Management’s view

Chief executive and managing director Mohan Jesudason said the company had spent more than a decade building a platform that can “connect and process data at scale and power real AI applications across utility and community infrastructure”.

He said the Mawson partnership meant X2M could go to market with a complete solution, including “a single agreement, a single bill, 5G connectivity, AI-driven utility management, full facilities operations and a 10-year managed service”.

That is a neat summary of the investment thesis: X2M wants to own the digital plumbing of smart communities, not merely supply a few taps and meters.

The investor read-through

This is a strategically interesting move for X2M because it broadens the company’s addressable market and could improve revenue visibility if the 10-year managed-service model is executed. It also gives X2M a clearer domestic growth narrative alongside its offshore utility deployments.

But the risks are equally clear. The MoU is non-binding, the revenue numbers depend heavily on adoption assumptions, and the ISCO model requires X2M to coordinate multiple service layers across connectivity, billing, utilities and facilities operations. That could lift revenue per estate, but it also raises execution demands.

For now, investors have been given a bigger story rather than a finished financial outcome. The next markers to watch are binding estate contracts, pricing detail, margin structure, capex requirements for private 5G deployment and evidence that operators are willing to hand one small-cap technology company such a central role in running their communities.